Health Trials

About this trial

The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI.

Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo.

Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.

Eligibility criteria

Qualifiers

Ischemic chest discomfort of ≥30 minutes duration, and

Onset of chest pain ≤12 hours prior to entry into the study, and

Disqualifiers

Age < 18 years

Any contraindication to undergo CMR imaging

Killip 4 (Cardiogenic shock on presentation)

Therapy with SGLT2i within last 8 weeks

Trial design

Treatments tested in this trial

  • Dapagliflozin 10mg Tab
  • CMR

Treatment groups

256 Participants
are divided into 2 treatment groups

Locations

1
University of Ottawa Heart InstituteK1Y 4W7, OttawaOntario, Canada

Sponsors and collaborators

Ottawa Heart Institute Research Corporation

Lead sponsor

Source ClinicalTrials.gov